Rashtriya Newsflash

Myotonic Dystrophy (DM) – Pipeline Insight, 2026

DelveInsight’s “Myotonic Dystrophy (DM) – Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies developing several pipeline drugs in the Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Myotonic Dystrophy treatment landscape. Learn more about the evolving Myotonic Dystrophy pipeline today @ https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Myotonic Dystrophy Pipeline Report

• Mexiletine (Namuscla), developed by Lupin, is currently in Phase III clinical trials for the treatment of myotonic dystrophy, representing one of the most advanced pipeline candidates targeting muscle stiffness associated with DM.

• Pitolisant (WAKIX), a selective histamine 3 (H3) receptor antagonist/inverse agonist developed by Harmony Biosciences, is being investigated in Phase II clinical trials for the treatment of Myotonic Dystrophy.

• ARO-DM1, Arrowhead Pharmaceuticals’ RNAi-based conjugate designed to silence DMPK mRNA in skeletal muscle, has entered Phase I clinical development, marking a significant step for gene-silencing approaches in DM1.

• DelveInsight’s Myotonic Dystrophy Pipeline Insight report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myotonic Dystrophy treatment.

• The leading Myotonic Dystrophy companies include AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others.

• Promising Myotonic Dystrophy therapies include Tideglusib, Mexiletine, Pitolisant, AOC 1001, DYNE-101, VX-670, ARO-DM1, PGN EDODM1, IONIS-877864, and others.

Download for updates and the latest revolution in Myotonic Dystrophy care @ Myotonic Dystrophy Clinical Trials Assessment

Myotonic Dystrophy Emerging Drugs Profile

Mexiletine: Lupin

Mexiletine, developed by Lupin under names like Mexiletine hydrochloride and Namuscla, is a class Ib antiarrhythmic drug primarily used for treating muscle stiffness associated with myotonic dystrophy. As a sodium channel antagonist, mexiletine works by blocking voltage-gated sodium channels in skeletal muscle fibers. This prevents excessive sodium influx, which is responsible for the delayed muscle relaxation characteristic of myotonia. By stabilizing the cell membrane and reducing repetitive firing in hyperexcitable muscle cells, mexiletine effectively alleviates muscle stiffness and cramping, offering symptomatic relief for patients with myotonic dystrophy. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of myotonic dystrophy.

Pitolisant: Harmony Biosciences

Pitolisant (WAKIX) is a selective histamine 3 (H3) receptor antagonist/inverse agonist. The mechanism of action of WAKIX is unclear; however, its efficacy could be mediated through its activity at H3 receptors, thereby increasing the synthesis and release of histamine, a wake-promoting neurotransmitter. WAKIX was designed and developed by Bioprojet (France). Harmony has an exclusive license from Bioprojet to develop, manufacture, and commercialize pitolisant in the United States. Currently, the drug is being investigated in Phase II clinical trial evaluation for the treatment of Myotonic Dystrophy.

ARO-DM1: Arrowhead Pharmaceuticals, Inc.

ARO-DM1 is an RNA interference (RNAi) conjugate designed to specifically silence DMPK mRNA in skeletal muscle. Published literature suggests that the silencing of aberrantly transcribed DMPK mRNA using ARO-DM1 may halt CUGexp-related spliceopathies in patients with DM1, leading to improved muscle strength and function. It belongs to a class of medicines called RNA therapeutics. The drug candidate is administered intravenously. ARO-DM1 is currently in the Phase I stage of development for the treatment of myotonic dystrophy.

For more information on the Myotonic Dystrophy Emerging Drugs Profile, download DelveInsight’s comprehensive Myotonic Dystrophy Pipeline Insight report.

The Myotonic Dystrophy Pipeline Report Provides

• Detailed insights about companies developing therapies for Myotonic Dystrophy, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Myotonic Dystrophy treatment.

• Myotonic Dystrophy companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Myotonic Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Myotonic Dystrophy market.

Learn more about Myotonic Dystrophy Drugs opportunities in our comprehensive Myotonic Dystrophy pipeline report @ Myotonic Dystrophy Unmet Needs

Myotonic Dystrophy Companies

There are 20+ key companies, such as AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others, developing therapies for Myotonic Dystrophy, with Lupin having its Myotonic Dystrophy drug candidate in the most advanced Phase III stage.

DelveInsight’s Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Myotonic Dystrophy products have been categorized under various Molecule types such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Discover the latest advancements in Myotonic Dystrophy treatment by visiting our website. Stay informed @ Myotonic Dystrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Myotonic Dystrophy Pipeline Report

• Coverage: Global

• Myotonic Dystrophy companies: AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others

• Myotonic Dystrophy Therapies: Tideglusib, Mexiletine, Pitolisant, AOC 1001, DYNE-101, VX-670, ARO-DM1, PGN EDODM1, IONIS-877864, and others

• Myotonic Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Myotonic Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Myotonic Dystrophy: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Myotonic Dystrophy – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Myotonic Dystrophy Key Companies

13. Myotonic Dystrophy Key Products

14. Myotonic Dystrophy Unmet Needs

15. Myotonic Dystrophy Market Drivers and Barriers

16. Myotonic Dystrophy Future Perspectives and Conclusion

17. Myotonic Dystrophy Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services